PT-141 dosing and timing: a clinical overview

TL;DR

• Standard FDA-approved dose is 1.75 mg as bremelanotide (Vyleesi) for premenopausal women with HSDD.
• Take about 45 minutes before anticipated activity — nausea peaks roughly 60 to 90 minutes in.
• Compounded PT-141 used off-label in men is not FDA-approved; bremelanotide as Vyleesi is the approved form.

What it is

PT-141 is the research name for bremelanotide, a melanocortin-4 receptor agonist (in plain English: a molecule that switches on a specific receptor in the brain involved in sexual desire). It is FDA-approved as Vyleesi for HSDD (hypoactive sexual desire disorder — persistent low sexual desire that causes personal distress) in premenopausal women. The same molecule is used in compounded form off-label for men with desire-related concerns, but that use is not FDA-approved. The distinction matters because the dosing and timing guidance below comes from the Vyleesi label and the RECONNECT trial.

How it works

Think of a light switch wired into the desire circuits of the brain. PT-141 does not pour electricity into the wall — it just flips the switch on. Unlike sildenafil, which works on blood flow downstream, PT-141 acts on melanocortin receptors in the central nervous system. That is why timing matters. The signal needs about 30 to 45 minutes to reach effective levels, peaks within roughly two hours, and then fades. Eating heavily right before dosing can slow the timing and worsen nausea, so a light snack about 30 minutes earlier is often suggested.

Who asks about it

The question usually comes from adults whose desire has shifted and is causing distress in their lives. For women, the Vyleesi pathway exists. For men, the conversation moves into off-label compounded use, which means a clinician evaluation, written informed consent, and a careful look at cardiovascular history. Most people asking want one thing first: how do I take it without feeling sick.

What the research says

The RECONNECT trial reported by Kingsberg and colleagues studied 1.75 mg subcutaneous bremelanotide in premenopausal women with HSDD. It found statistically significant improvements in desire and reduced distress versus placebo. Nausea was the most common reported side effect, occurring in about 4 in 10 participants, usually mild to moderate and concentrated in the first hour or two after dosing. Most other side effects were also dose-related and tied to the early window.

What to know before considering it

PT-141 can raise blood pressure transiently and is not appropriate for people with uncontrolled hypertension or cardiovascular disease. Skin darkening can occur with repeated use, especially in those with darker baseline skin tone. The Vyleesi label limits use to 8 doses per month, with at least 24 hours between doses, and a maximum of one dose in any 24-hour period. Nausea management is the most common reason people stop early — pacing the dose, hydration, and a light snack help some people.

The Halftime POV

PT-141 is not a quick fix and not a daily medication. It is an as-needed tool with a narrow timing window and a real side-effect profile. Used thoughtfully, with a clinician and the right dose schedule, it can be a useful option. Used casually, the nausea alone will end the experiment.

Related reading:

• PT-141 side effects: what to expect
• PT-141: what it is
• Bremelanotide (Vyleesi): FDA-approved for women with HSDD

FAQ

What is the FDA-approved PT-141 dose? Bremelanotide (Vyleesi) is FDA-approved at 1.75 mg subcutaneous as-needed for premenopausal women with HSDD, taken about 45 minutes before anticipated activity.

How long does PT-141 last? Half-life is roughly 2 hours, with peak effect within about 2 hours of dosing. The desire effect itself can extend longer in some people.

How many doses are allowed per month? The Vyleesi label sets a maximum of 8 doses per month, with at least 24 hours between doses.

Why does timing affect nausea? Nausea peaks about 60 to 90 minutes after dosing. Eating a light snack about 30 minutes before may reduce it for some people.

Is compounded PT-141 for men FDA-approved? No. Bremelanotide is FDA-approved as Vyleesi for women with HSDD only. Compounded PT-141 used for men is off-label and not FDA-approved.

Disclaimer

This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.

Get updates

Halftime Health is launching soon. Join the waitlist for updates.

Sources

• U.S. Food and Drug Administration. "Vyleesi (bremelanotide injection) Prescribing Information." 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
• Kingsberg SA, Clayton AH, Portman D, et al. "Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials (RECONNECT)." Obstetrics & Gynecology, 2019. https://pubmed.ncbi.nlm.nih.gov/31618132/
• Clayton AH, Althof SE, Kingsberg S, et al. "Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial." Women's Health, 2016. https://pubmed.ncbi.nlm.nih.gov/26937669/